MedTrace Logo

PMCF Registry to Describe the Safety and Performance of p64, p48 MW and p64 MW in France

NCT07748572 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-08-05

No results posted yet for this study

Summary

To evaluate safety and performance of the phenox GmbH Flow Diverter p64, p64 MW, and p48MW in France, this registry will include subjects with intracranial aneurysms (anterior and posterior) who are treated with a phenox GmbH Flow Diverter. The subjects will be treated according to the standard of care in the participating sites.

Conditions

  • Intracranial Aneurysms

Interventions

DEVICE

Aneurysm treatment with a Flow Modulation Device

Treatment of an intracranial aneurysm (anterior and posterior circulation) with a p64, p48 MW, or p64 MW Flow Modulation Device.

Sponsors & Collaborators

  • Phenox GmbH

    lead INDUSTRY

Principal Investigators

  • Laurent Pierot, Prof. · CHU de Reims

  • Laurent Spelle, Prof. · Hôpital Bicêtre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-07
Primary Completion
2028-10-31
Completion
2028-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748572 on ClinicalTrials.gov